A multicentre trial of voltaren in the treatment of rheumatoid arthritis

  • OP Quantock
  • PG Joubert
  • DF Du P Louw
  • DF Marais
  • WA McDonald Scott
  • FO Muller

Abstract

Voltaren, a compound with analgesic, anti-inflammatory and antipyretic properties, has been compared at two dose levels-25 mg t.d.s. and 50 mg t.d.s. with indomethacin 25 mg t.d.s. and acetylsalicylic acid 1 500 mg t.d.s. Ninety-one patients with definite or classical rheumatoid arthritis took part in this study. The trial was a doubleblind cross-over study, with each  medication being given for one week. Patients were washed out for one week prior to the first active treatment. Each patient received only two of the four possible treatments. Voltaren in a dose of 25 mg t.d.s. was found to improve the symptoms of rheumatoid arthritis to a greater degree than indomethacin or acetylsalicylic acid. Voltaren 50 mg t.d.s. evoked a greater response than acetylsalicylic acid and was at least as efficacious as indomethacin. Voltaren was better tolerated than either indomethacin or acetylsalicylic acid. The incidence of gastro-intestinal side-effects was similar with Voltaren and indomethacin, and half that produced by acetylsalicylic acid. Some evidence of possible drug interaction was found.

S. Afr. Med. J., 48, 2013 (1974).

Author Biographies

OP Quantock
Arthritis Clinic, Groote Schuur Hospital, Cape Town
PG Joubert
Department of Orthopaedic Surgery, Karl Bremer Hospital, Tiervlei, CP
DF Du P Louw
Department of Orthopaedic Surgery, Karl Bremer Hospital, Tiervlei, CP
DF Marais
Pretoria
WA McDonald Scott
Department of Medicine, Addington Hospital, Durban
FO Muller

Department of Pharmacology, University of the Orange Free
State, Bloemfontein, OFS

Published
2018-04-17
Section
Articles

Journal Identifiers


eISSN: 0256-95749
print ISSN: 2078-5135